International Prognostic Index

Last updated

The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin lymphoma. Previous to IPI's development, the primary consideration in assessing prognosis was the Ann Arbor stage alone, but this was increasingly found[ by whom? ] to be an inadequate means of predicting survival outcomes, and so other factors were studied.[ citation needed ]

Contents

History

In 1984, the first prognostic indicator for advanced non-Hodkin lymphoma was developed. An information theory guided, computer search and evaluation procedure entropy minimax was employed to discover the largest sub-groupings for which survival is as extreme as possible. [1] In the clinical trials analyzed retrospectively and containing a large fraction of patients not matching the 'good' - of 'good' (Karnofsky status >80 and 'A" Symptoms and SGOT <36 U/L), 'poor' (Karnofsky status <70 or Night sweats) and 'intermediate' (All Remaining) prognosis patterns identified, a significant difference was found between the survival of patients with and those without a complete response to therapy. The authors concluded that trials using a patient mix weighted toward good prognosis will not find such a difference.

In 1993, a retrospective analysis was performed on 2031 patients with aggressive non-Hodgkin lymphoma, of all ages, treated with a doxorubicin-based chemotherapy regimen such as CHOP between 1982 and 1987. [2] Several patient characteristics were analyzed to determine whether they were associated with differences in survival, and the factors that emerged as significant were, in addition to the Ann Arbor stage: age, elevated serum lactate dehydrogenase (LDH), performance status, and number of extranodal sites of disease.

International Prognostic Index

One point is assigned for each of the following risk factors:[ citation needed ]

The sum of the points allotted correlates with the following risk groups:

Age-Adjusted IPI

A simplified index can be used when comparing patients within an age group (i.e. 60 or younger, or over 60) and includes only 3 of the above factors:[ citation needed ]

The sum of the points allotted correlates with the following risk groups:

Although the IPI has shown itself to be a useful clinical tool, widely used by oncologists and a mainstay of risk stratification in clinical trials for lymphoma, it should be kept in mind that it was developed prior to the use of rituximab, which is now included with anthracycline-based combination chemotherapy as of the standard of care in B-cell lymphomas (the majority of non-Hodgkin lymphomas). Rituximab has significantly improved the outcomes of lymphoma patients; and its effect on the prognostic value of the IPI is uncertain. Future development of a more rigorous prognostic index may thus be useful.

Follicular Lymphoma International Prognostic Index (FLIPI)

Given the success of the IPI for intermediate grade lymphomas, an effort was undertaken to develop a similar prognostic index for the most common low-grade lymphoma, follicular lymphoma. The prognostic factors that emerged from this were: age, stage, number of lymph node areas involved, serum hemoglobin level, and serum LDH. [3]

One point is assigned for each of the following adverse prognostic factors:[ citation needed ]

The sum of the points allotted correlates with the following risk groups:

Mantle Cell Lymphoma International Prognostic Index (MIPI)

An effort was more recently undertaken to identify a similar prognostic index predictive of outcome in advanced mantle cell lymphoma. There were four factors found to have independent prognostic relevance: age, performance status, LDH, and white blood cell count (WBC). [4]

The point values are assigned as follows:

The sum of the allotted points correlates with the following risk groups:

See also

References

  1. Reichert, T.A.; Christensen, R.A.; Bartolucci, A.A.; Walker, C. (1985). "Patterns of survival in advanced non-Hodgkin's lymphoma" . In Cavalli, F.; Bonadonna, G.; Rozencweig, M. (eds.). Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. The Second International Conference on Malignant Lymphomas, Lugano, Switzerland, June 13 – 16, 1984. Developments in Oncology. Vol. 32. Boston: Martinus Nijhoff Publishers. pp. 233–241. doi:10.1007/978-1-4613-2607-6_24. ISBN   978-0-89838-727-8. Archived from the original on 2025-05-28. Retrieved 2025-05-28.
  2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993-09-30). "A Predictive Model for Aggressive Non-Hodgkin's Lymphoma". The New England Journal of Medicine . 329 (14). Massachusetts Medical Society: 987–994. doi:10.1056/NEJM199309303291402. PMID   8141877. Archived from the original on 2025-05-28. Retrieved 2025-05-28.
  3. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. (2004-09-01). "Follicular Lymphoma International Prognostic Index". Blood . 104 (5). American Society of Hematology: 1258–1265. doi:10.1182/blood-2003-12-4434. hdl: 11380/584210 . PMID   15126323. Archived from the original on 2025-05-28. Retrieved 2025-05-28.
  4. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. (2008-01-15). "A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma" . Blood . 111 (2). American Society of Hematology: 558–565. doi:10.1182/blood-2007-06-095331. PMID   17962512. Archived from the original on 2025-05-28. Retrieved 2025-05-28.